Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Zai Lab Raises $261 Million; Plans China NDA Filing for Ripretinib in Mid-2020

publication date: Jan 24, 2020

Zai Lab, a Shanghai novel commercial stage biopharma, raised $261 million in a secondary offering. The company reported it held $68.7 million of cash on September 30, 2019 and spent $110 million on R&D in the first nine months of last year, a near-doubling from 2018 due to new projects and ongoing clinical trials. Zai also announced it expects to submit a China NDA for ripretinib by mid-2020 to treat gastrointestinal stromal tumors. In late December, Zai reported China approval for Zezula, a PARP inhibitor and Zai's first drug to launch in China. More details....

Stock Symbol: (NSDQ: ZLAB)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital